Search Results - "Kearns, Gregory L."

Refine Results
  1. 1

    Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials by Kearns, Gregory L, Artman, Michael

    Published in Current pharmaceutical design (01-01-2015)
    “…Over the past 30 years, much has been learned about the impact of development on drug disposition (i.e., pharmacokinetics). This is not true concerning drug…”
    Get more information
    Journal Article
  2. 2

    The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst by Pearce, Robin E, Cohen-Wolkowiez, Michael, Sampson, Mario R, Kearns, Gregory L

    Published in Drug metabolism and disposition (01-09-2013)
    “…Despite metronidazole's widespread clinical use since the 1960s, the specific enzymes involved in its biotransformation have not been previously identified…”
    Get full text
    Journal Article
  3. 3

    Impact of the CYP2C1917 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect by KEARNS, Gregory L, LEEDER, J. Steven, GAEDIGK, Andrea

    Published in Drug metabolism and disposition (01-06-2010)
    “…The impact of the CYP2C19*17 allele on the pharmacokinetics of pantoprazole and omeprazole in previously studied children (n = 40) was explored. When…”
    Get full text
    Journal Article
  4. 4

    Evaluating palatability in young children: a mini-review of relevant physiology and assessment techniques by Schluterman, Haley M, Linardos, Constance G, Drulia, Teresa, Marshall, James D, Kearns, Gregory L

    Published in Frontiers in pediatrics (08-02-2024)
    “…The palatability of pediatric pharmaceutical products plays a crucial role of influencing medication compliance. Rejection of unpalatable medications can…”
    Get full text
    Journal Article
  5. 5

    Peppermint oil effects on the gut microbiome in children with functional abdominal pain by Thapa, Santosh, Luna, Ruth Ann, Chumpitazi, Bruno P., Oezguen, Numan, Abdel‐Rahman, Susan M., Garg, Uttam, Musaad, Salma, Versalovic, James, Kearns, Gregory L., Shulman, Robert J.

    Published in Clinical and translational science (01-04-2022)
    “…Peppermint oil (PMO) is effective in the treatment of functional abdominal pain disorders, but its mechanism of action is unclear. Evidence suggests PMO has…”
    Get full text
    Journal Article
  6. 6

    How to Conduct Clinical Trials in Children: A Tutorial by Shakhnovich, Valentina, Hornik, Christoph P., Kearns, Gregory L., Weigel, Jaylene, Abdel‐Rahman, Susan M.

    Published in Clinical and translational science (01-05-2019)
    “…Despite a growing interest in, and commitment to, implementing pediatric clinical trials, approximately one in every five trials in children fails because of…”
    Get full text
    Journal Article
  7. 7

    Utility of the 13C‐pantoprazole breath test as a CYP2C19 phenotyping probe for children by Feldman, Keith, Kearns, Gregory L., Pearce, Robin E., Abdel‐Rahman, Susan M., Steven Leeder, James, Friesen, Alec, Staggs, Vincent S., Gaedigk, Andrea, Weigel, Jaylene, Shakhnovich, Valentina

    Published in Clinical and translational science (01-05-2022)
    “…The 13C‐pantoprazole breath test (PAN‐BT) is a safe, noninvasive, in vivo CYP2C19 phenotyping probe for adults. Our objective was to evaluate PAN‐BT…”
    Get full text
    Journal Article
  8. 8

    Developmental Changes in Pharmacokinetics and Pharmacodynamics by den Anker, John, Reed, Michael D., Allegaert, Karel, Kearns, Gregory L.

    Published in Journal of clinical pharmacology (01-10-2018)
    “…Effective drug therapy to optimally influence disease requires an understanding of a drug's pharmacokinetic, pharmacodynamic, and pharmacogenomic…”
    Get full text
    Journal Article
  9. 9

    Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA by Bajcetic, Milica, Kearns, Gregory L, Jovanovic, Ida, Brajovic, Milan, van den Anker, John N

    Published in Current pharmaceutical design (01-01-2015)
    “…The paucity of marketed drug products that have been adequately studied in infants and children and subsequently, licensed (or labeled) for pediatric use has…”
    Get more information
    Journal Article
  10. 10
  11. 11

    BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION by PEARCE, Robin E, LEEDER, J. Steven, KEARNS, Gregory L

    Published in Drug metabolism and disposition (01-06-2006)
    “…Fluticasone propionate (FTP) is a synthetic trifluorinated glucocorticoid with potent anti-inflammatory action that is commonly used in patients with asthma…”
    Get full text
    Journal Article
  12. 12

    Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics by Ward, Robert M., Kearns, Gregory L.

    Published in Paediatric drugs (01-04-2013)
    “…Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications for treatment of adults and children. Their effectiveness for…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics by Friesen, Craig A, Neilan, Nancy A, Schurman, Jennifer V, Taylor, Debra L, Kearns, Gregory L, Abdel-Rahman, Susan M

    Published in BMC gastroenterology (11-05-2009)
    “…We have previously demonstrated the clinical efficacy of montelukast in a randomized double-blind controlled cross-over trial in patients with dyspepsia in…”
    Get full text
    Journal Article
  15. 15

    Targeted metabolomic profiling indicates structure-based perturbations in serum phospholipids in children with acetaminophen overdose by Bhattacharyya, Sudeepa, Pence, Lisa, Yan, Ke, Gill, Pritmohinder, Luo, Chunqiao, Letzig, Lynda G, Simpson, Pippa M, Kearns, Gregory L, Beger, Richard D, James, Laura P

    Published in Toxicology reports (01-01-2016)
    “…Phospholipids are an important class of lipids that act as building blocks of biological cell membranes and participate in a variety of vital cellular…”
    Get full text
    Journal Article
  16. 16

    Cytokines and Toxicity in Acetaminophen Overdose by James, Laura P., Simpson, Pippa M., Farrar, Henry C., Kearns, Gregory L., Wasserman, Gary S., Blumer, Jeffrey L., Reed, Michael D., Sullivan, Janice E., Hinson, Jack A.

    Published in Journal of clinical pharmacology (01-10-2005)
    “…Several cytokines have been reported to have hepatoprotective properties in animal models of acetaminophen toxicity. To investigate the relationships of…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain by Shulman, Robert J., Chumpitazi, Bruno P., Abdel‐Rahman, Susan M., Garg, Uttam, Musaad, Salma, Kearns, Gregory L.

    Published in British journal of clinical pharmacology (01-03-2022)
    “…Aims Little is known regarding the pharmacokinetics and pharmacodynamics of menthol, the active ingredient in peppermint oil (PMO). Our aim was to investigate…”
    Get full text
    Journal Article
  19. 19

    Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design by Leroux, Stéphanie, Turner, Mark A., Guellec, Chantal Barin-Le, Hill, Helen, van den Anker, Johannes N., Kearns, Gregory L., Jacqz-Aigrain, Evelyne, Zhao, Wei

    Published in Clinical pharmacokinetics (01-12-2015)
    “…Background and Objective The use of an opportunistic (also called scavenged) sampling strategy in a prospective pharmacokinetic study combined with population…”
    Get full text
    Journal Article
  20. 20